Phase 1 Autism Spectrum Disorder Trial, Recruiting (NCT05015439)

Phase 1 Autism Spectrum Disorder Trial, Recruiting NCT05015439 Sponsor: Johns Hopkins University Condition: Autism Spectrum Disorder

Printed from Voxsanity (voxsanity.com.au) — NCT05015439 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Autism Spectrum Disorder

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Autism Spectrum Disorder (ASD) based on standard diagnostic guidelines (DSM-5).
You have a significant mood disorder, sleep problems, or show signs of agitation, aggression, or other challenging behaviors that are affecting your daily life and wellbeing, as assessed during a psychiatric interview.

Who may not be able to join:

You have a history of alcohol or drug use disorder.
You test positive for cannabis (marijuana/THC) in a urine test at the start of the study.
You are currently pregnant, breastfeeding, or planning to become pregnant during the trial or within three months of finishing it.
You have an unstable liver condition or disease.
You are taking certain medications that could interact with CBD (cannabidiol) in a way that significantly changes how those medications work in your body — for example, a seizure medication called clobazam (confirm with trial site for a full list of affected medications).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elizabeth Wise, MD, Johns Hopkins University

Phone: 410-550-6207

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05015439

Sponsor: Johns Hopkins University

Phase: Phase 1

Status: Recruiting

Condition: Autism Spectrum Disorder

Trial contact: 410-550-6207

More information: https://clinicaltrials.gov/study/NCT05015439

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Autism Spectrum Disorder (ASD) based on standard diagnostic guidelines (DSM-5).
You have a significant mood disorder, sleep problems, or show signs of agitation, aggression, or other challenging behaviors that are affecting your daily life and wellbeing, as assessed during a psychiatric interview.

Who may not be able to join:

You have a history of alcohol or drug use disorder.
You test positive for cannabis (marijuana/THC) in a urine test at the start of the study.
You are currently pregnant, breastfeeding, or planning to become pregnant during the trial or within three months of finishing it.
You have an unstable liver condition or disease.
You are taking certain medications that could interact with CBD (cannabidiol) in a way that significantly changes how those medications work in your body — for example, a seizure medication called clobazam (confirm with trial site for a full list of affected medications).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Johns Hopkins University

Registry

ClinicalTrials.gov

Start date

20 April 2023

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov